LONDON, United Kingdom — For patients with atypical hemolytic uremic syndrome (HUS), the improvement in estimated glomerular filtration rate (eGFR) is significantly better when eculizumab (Soliris, ...

AGNSS Recommends Soliris® (eculizumab) for aHUS and Concludes “Eculizumab would help save lives and improve the quality of life for children and adults with atypical haemolytic uraemic syndrome” ...

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Atypical Hemolytic Uremic Syndrome pipeline constitutes 5+ key companies continuously working towards developing 5+ ...

"Atypical Hemolytic Uremic Syndrome Pipeline"Following the success of terminal complement inhibitors like eculizumab and ravulizumab, the therapeutic focus in 2025 has shifted towards developing ...

ISTANBUL, Turkey — Eculizumab improves renal outcomes in patients with atypical hemolytic uremic syndrome, including patients on dialysis, intermediate results of a highly-anticipated new study have ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Atypical hemolytic uremic syndrome is a ...

Please provide your email address to receive an email when new articles are posted on . Registry data showed efficacy of ravulizumab was similar to that of eculizumab. No unexpected adverse events ...

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License ...

PARSIPPANY, N.J. and INCHEON, Korea, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Samsung Bioepis Co., ...

The Key Atypical Hemolytic Uremic Syndrome Companies in the market include - Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others. The Atypical Hemolytic Uremic ...

SEATTLE -- An agent that works similarly to the approved myasthenia gravis (MG) drug eculizumab (Soliris) but with a longer dosing interval, and made by the same company, proved its mettle in a ...

CHESHIRE, Conn., Aug 01, 2014 (BUSINESS WIRE) -- Alexion Pharmaceuticals ALXN-1.20% today announced that the European Commission has granted orphan drug designation (ODD) to Soliris® (eculizumab) for ...